Last reviewed · How we verify
TRANDOLAPRIL
At a glance
| Generic name | TRANDOLAPRIL |
|---|---|
| Drug class | Angiotensin Converting Enzyme Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Boxed warnings
- WARNING: FETAL TOXICITY When pregnancy is detected, discontinue trandolapril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (See WARNINGS: Fetal Toxicity .)
Common side effects
- Headache
- Upper Respiratory Tract Infection
- Cough
- AV Block First Degree
- Constipation
- Dizziness
- Fatigue
- Increased Liver Enzymes
- Chest Pain
- Back Pain
- Upper Respiratory Tract Congestion
- Bradycardia
Serious adverse events
- Angioedema
- Myocardial Infarction
- AV Block Second Degree
- Bundle Branch Block
- Hypotension
- Syncope/Near Syncope
- Palpitations
- Premature Ventricular Contractions
- Tachycardia
- Angina
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Trandolapril 4 mg Tablet Under Non-Fasting Conditions (PHASE1)
- Trandolapril 4 mg Tablet Under Fasting Conditions (PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (PHASE4)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRANDOLAPRIL CI brief — competitive landscape report
- TRANDOLAPRIL updates RSS · CI watch RSS